Attractive Healthcare stock of Yesterday - Sucampo Pharmaceuticals, Inc. (SCMP)

Galtero Lara
Enero 13, 2018

Is Sucampo Pharmaceuticals, Inc. They issued a buy rating and a $14.00 target price for the company.

These analysts also forecasted Growth Estimates for the Current Quarter for SCMP to be -48.5%. The firm now has a $18.00 target price on the biopharmaceutical company's stock, up from their prior target price of $14.00. Mizuho upgraded the stock to "Buy" rating in Thursday, December 22 report. Sucampo Pharmaceuticals, Inc. (SCMP) has declined 5.30% since January 12, 2017 and is downtrending. Maxim Group cut shares of Sucampo Pharmaceuticals to a hold rating in a research note on Monday, January 1st. Finally, Globeflex Capital L P increased its stake in shares of Sucampo Pharmaceuticals by 0.3% in the second quarter. CRAI's profit will be $2.76M for 35.77 P/E if the $0.34 EPS becomes a reality.

When we look at the Analyst Recommendations of the stock, the company has 2.71 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.

The 21 analysts offering 12-month price forecasts for Boeing have a median target of 305.00, with a high estimate of 350.00 and a low estimate of 203.00.

More news: Sucampo Pharmaceuticals, Inc. (SCMP), Equinix, Inc. (REIT) (EQIX)

Sucampo Pharmaceuticals, Inc. (SCMP) shares Jumped 0.54% and ended the day at $18.5. The stock traded with the volume of 6.06 Million shares yesterday. The corporation has a market cap of US$862.96 Million. At the same time as, it has debt to equity ratio of 0.00 and similar long term debt to equity ratio was 7.37. The stock traded within a range of $18.00 and $18.75. (NASDAQ:CHRS) to report earnings on March, 12.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP)'s earnings per share has been growing at a 24.8 percent rate over the past 5 year when average revenue increase was noted as 33.3 percent. Sucampo Pharmaceuticals had a negative net margin of 60.24% and a positive return on equity of 74.58%. The business had revenue of $61.27 million during the quarter, compared to analysts' expectations of $58.05 million. The difference between the actual and Estimated EPS is $0.02. They expect $-0.90 EPS, up 47.37% or $0.81 from last year's $-1.71 per share.

In other Sucampo Pharmaceuticals news, insider Peter A. Kiener sold 50,000 shares of the stock in a transaction that occurred on Thursday, December 7th. Following the completion of the sale, the insider now directly owns 52,023 shares in the company, valued at approximately $858,379.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Point72 Asset Management L.P. acquired a new position in Sucampo Pharmaceuticals during the 3rd quarter valued at about $21,989,000. JPMorgan Chase & Co. bought a new stake in Sucampo Pharmaceuticals in the second quarter valued at about $117,000. Arizona State Retirement System now owns 13,100 shares of the biopharmaceutical company's stock valued at $138,000 after buying an additional 200 shares during the period. WallachBeth Capital maintained Sucampo Pharmaceuticals, Inc. The Bank Of America Corp holds 28,626 shares with $383,000 value, down from 71,700 last quarter. It also upped Qualcomm Inc (Call) (NASDAQ:QCOM) stake by 1.81 million shares and now owns 6.29M shares. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company's stock valued at $209,000 after purchasing an additional 790 shares during the last quarter. Finally, Thrivent Financial For Lutherans lifted its holdings in Sucampo Pharmaceuticals by 11.3% during the second quarter. If you are viewing this story on another site, it was illegally stolen and republished in violation of worldwide copyright & trademark laws. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & global copyright legislation. The correct version of this piece can be accessed at

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The Company's product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

Otros informes por

Discuta este artículo